Ken Griffin Trevi Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.58 - $3.51 $1,548 - $2,106	600 New	600 $2,000
Q1 2024 May 15, 2024	BUY	$1.3 - $3.7 $520 - $1,480	400 Added 22.22%	2,200 $7,000
Q4 2023 Feb 14, 2024	BUY	$1.06 - $2.05 $1,908 - $3,689	1,800 New	1,800 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.8 - $3.44 $180 - $344	-100 Reduced 9.09%	1,000 $2,000
Q1 2023 May 15, 2023	SELL	$1.69 - $2.97 $169 - $297	-100 Reduced 8.33%	1,100 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.61 - $2.42 $1,932 - $2,904	1,200 New	1,200 $2,000

57.1M

136K

5.4K

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $160M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.